TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$120.55 USD
+1.58 (1.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $120.51 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, TransMedics Group, Inc. has a market cap of $4.06B, which represents its share price of $118.97 multiplied by its outstanding shares number of 34.09M. As a mid-cap company, TMDX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TMDX 120.55 +1.58(1.33%)
Will TMDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMDX
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?
Other News for TMDX
Morgan Stanley Raises Price Target for TMDX to $123 | TMDX Stock News
What TransMedics Just Taught Me About Trusting The Algorithm
TransMedics: Continued Strength Suggests Further Upside
TransMedics Group Inc (TMDX) Announces Inducement Grants to New Employees | TMDX stock news
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | TMDX Stock News